Technical analyst Anil Singhvi has maintained 'buy' rating on Cadila Healthcare Limited stock with an intra-day target of Rs 820.

According to analyst, the investors can purchase the stock with a stop loss of Rs 761.

The stock of the company, on January 17, closed at Rs 774.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 809.45 and a low of Rs 422.94 on BSE.

Current EPS & P/E ratio stood at 30.72 and 25.81 respectively.

Cadila Healthcare Ltd has declared that its board meeting will take place on January 18, inter alia, to consider unaudited financial outcomes for the three month period and nine months ended December 2010.

For the three month period ended September 2010, Cadila Healthcare has registered an increase of 29.50% in its consolidated net profit, which stood at Rs 1,708.4 million as compared to Rs 1,319.2 million during the same quarter of 2009.

Its net sales during the period surged 21.23% to Rs 11,063.2 million for the period under review.

On standalone basis, the company's net profit grew by 45.98% to Rs 1,816 million for the three month period ended Sep 2010 as against Rs 1,244 million for the same period of 2009.